PEN - Penumbra, Inc.

NYSE - NYSE 延遲價格。貨幣為 USD。
+0.97 (+0.30%)
收市:04:00PM EDT
320.50 -1.33 (-0.41%)
收市後: 07:59PM EDT
買盤0.00 x 900
賣出價0.00 x 4000
今日波幅318.60 - 323.00
52 週波幅114.86 - 324.38
Beta 值 (5 年,每月)0.54
市盈率 (最近 12 個月)2,011.44
每股盈利 (最近 12 個月)0.16
業績公佈日2023年8月02日 - 2023年8月07日
遠期股息及收益率無 (無)
1 年預測目標價321.44
  • Insider Monkey

    Should You Invest in Penumbra (PEN)?

    ClearBridge Investments, an investment management company, released its “ClearBridge SMID Cap Growth Strategy” first quarter 2023 investor letter. A copy of the same can be downloaded here. In the first quarter, the strategy underperformed the Russell 2500 Growth benchmark. On an absolute basis, the strategy gained in six of the 10 sectors it was invested in […]

  • Insider Monkey

    12 Stocks To Sell According to Motley Fool

    In this article, we will be looking at 12 stocks to sell according to Motley Fool. To skip our detailed analysis of current market dynamics heading into 2023, you can go directly to see the 5 Stocks To Sell According to Motley Fool. Motley Fool Asset Management focuses on high-quality growth companies, and it is constantly […]

  • Insider Monkey

    15 Biggest Medical Device Companies in the World

    In this article, we will take a look at the 15 biggest medical device companies in the world. If you want to skip our introduction to the industry, then take a look at 5 Biggest Medical Device Companies in the World. The medical device market comprises companies that manufacture equipment used in diagnosing, treating and surveillance […]

  • Benzinga

    Penumbra's Lightning Flash Launch Pushed Into Next Year, Trims FY22 Forecasts

    Penumbra Inc (NYSE: PEN) posted Q3 FY22 revenue of $213.7 million, +12.4% Y/Y (up 15.1% in constant currency), beating the consensus of $212.28 million. Revenue from sales of vascular products grew 17% (18.8%) to $123.4 million. Revenue from sales of neuro products grew 6.7% (10.5%) to $90.3 million. The gross margin was almost stagnant at 63%. The company reported an adjusted operating income of $7.8 million, down from $8.8 million posted a year ago. The company reported an adjusted EPS of $0.0

  • Benzinga

    Penumbra Ramps Up Efforts To Launch Indigo Aspiration System In Japan

    Penumbra Inc (NYSE: PEN) and Japan-based medical device manufacturer Asahi Intecc Co will collaborate to introduce Penumbra's Indigo Aspiration System into the Japanese market upon regulatory approval. The Indigo Aspiration System can be used to remove emboli and thrombi from peripheral arterial and venous systems vessels and treat pulmonary embolism. Indigo is a minimally-invasive device that enables blood flow restoration in cases such as acute limb ischemia and venous thrombus. Related: Citin

  • Benzinga

    Citing 'Lightning Fast Growth,' Needham Upgrades This Vascular Device Company

    Needham upgraded Penumbra Inc (NYSE: PEN) to Buy from Hold, with a price target of $244. The analyst notes that management indicated PEN is seeing stronger growth in 3Q22 due to an improvement in hospital staffing, share gains, or a combination of these. Penumbra recently announced European approval for RED Reperfusion Catheters, which are part of the company's Penumbra System, a fully integrated mechanical aspiration thrombectomy system designed to restore blood flow in acute ischemic stroke pa

  • Insider Monkey

    12 Best Medical Device Stocks To Buy Now

    In this piece, we will take a look at the twelve best medical device stocks to buy now. If you want to skip our introduction to the industry and jump to the top five stocks in this list, then take a look at 5 Best Medical Device Stocks To Buy Now. The outset of the […]

  • Benzinga

    With Sustained Double-Digit Growth Profile, RBC Starts Coverage On This MedTech Stock

    RBC Capital Markets initiated coverage on Penumbra Inc (NYSE: PEN) with an Outperform rating and a price target of $195 (59% implied upside). The analysts write that Penumbra is a medical device company operating in attractive, high-growth, under-penetrated neuro and vascular end markets. RBC writes that PEN is investing to position itself for continued growth, but the company is profitable with a clear pathway for expanding margins. Related: Despite Seeing Accelerated 2023 Growth, This Analyst